Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6753576 | 0.80 | PSEN1 (0.42) | MAPK9MAPK10LSSCXCR3PSEN1 | |
| SCHEMBL3546605 | 0.80 | CCR2 (0.51) | MAPK9MAPK10PPARGPPARAMEN1 | |
| SCHEMBL3480150 | 0.77 | MAPK9 (0.56) | MAPK9MAPK10MEN1KMT2ACCR2 | |
| SCHEMBL3541193 | 0.77 | LSS (0.45) | LSSPPARGPPARAMEN1CYP1A2 | |
| SCHEMBL11929041 | 0.77 | MAPK9 (0.41) | MAPK9MAPK10PPARGPPARAMEN1 | |
| SCHEMBL3480241 | 0.77 | MAPK9 (0.46) | MAPK9MAPK10MEN1KMT2ACCR2 | |
| SCHEMBL6753601 | 0.76 | SCN9A (0.38) | NPSR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3479959 | 0.76 | MAPK9 (0.49) | MAPK9MAPK10MEN1KMT2ACCR2 | |
| SCHEMBL3479910 | 0.76 | MAPK9 (0.53) | MAPK9MAPK10PPARGPPARAMEN1 | |
| SCHEMBL3479914 | 0.76 | MAPK9 (0.53) | MAPK9MAPK10PPARGPPARAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683078-B2 | Arylsulfonamide derivatives as C-Jun-N-Terminal Kinases (JNK's) inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-03-23 | — | — | US | claimed |
| US-20040248886-A1 | Pharmaceutically active sulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors | MERCK SERONO SA (CH) | 2004-12-09 | — | — | US | claimed |
| EP-1409483-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2004-04-21 | — | — | EP | claimed |
| WO-2003010164-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-02-06 | — | — | WO | claimed |
| US-7683078-B2 | Arylsulfonamide derivatives as C-Jun-N-Terminal Kinases (JNK's) inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-03-23 | — | — | US | disclosed |
| US-20100029719-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-1409483-B1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | SERONO LAB (CH) | 2008-12-31 | — | — | EP | disclosed |
| US-20040248886-A1 | Pharmaceutically active sulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors | MERCK SERONO SA (CH) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248886-A1 | Pharmaceutically active sulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors | MAPK1, MAPK3, MAP3K2 | MAPK9 28/4885MAPK10 49/4885LSS 2553/4885 |
| US-20100029719-A1 | ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS | MAPK1, MAPK3, MAP3K2 | MAPK9 29/4885MAPK10 44/4885LSS 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.